Markets
MRK

Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)

An image of people surrounding a sheet of paper with many charts on it
Credit: Shutterstock photo

Nektar Therapeutics ' NKTR shares increased more than 11% on Feb 14 after the company announced a global strategic collaboration agreement with Bristol-Myers Squibb BMY . Per the agreement, both companies will jointly develop and commercialize the lead immuno-oncology candidate, NKTR-214, of the former in combination with the latter's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab).

Pursuant to the contract, Nektar is entitled to receive an upfront payment of $1.85 billion, which includes a payment of $1 billion in cash and an equity investment of $850 million. Nektar will also get an additional $1.78-billion potential payment on achievement of certain developmental and sale-based milestones.

Both Nektar and Bristol-Myers will share profits in the respective ratios of 65% and 35% from the potential sales of NKTR-214, worldwide.

On a positive note, Nektar not only retains its ownership of the candidate but can also continue to collaborate with other companies for its further development. While Nektar will jointly commercialize NKTR-214/Opdivo combinations in the United States as well as major markets in the EU and Japan, Bristol-Myers is entitled to solely commercialize the combinations in the other global markets.

We remind investors that Nektar is already evaluating NKTR-214/Opdivo in phase I/II PIVOT studies across five tumor types (melanoma, kidney, colorectal, bladder and non-small cell lung cancer) and eight potential indications. With this latest deal with Bristol Myers, it has been agreed upon by both companies to evaluate NKTR-214/Opdivo and NKTR-214/Opdivo plus Yervoy combinations in more than 20 cancer indications across nine tumor types.

In November 2017, the two companies reported a positive interim data from dose-escalation part of the study, evaluating the safety and efficacy of the combo therapy on patients with melanoma, renal cell carcinoma and non-small cell lung cancers.

Nektar's shares have significantly outperformed the industry in a year's time. The stock has skyrocketed 532.9% compared with the industry's 2.5% increase.

Importantly, Nektar is also conducting a phase I/II PROPEL study to evaluate the efficacy and safety of NKTR-214 in combination with Roche's Tecentriq (atezolizumab) and Merck's Keytruda (pembrolizumab). Notably, this PROPEL study complements the company's ongoing PIVOT trial.

Importantly, Nektar is also conducting a phase I/II PROPEL study to evaluate the efficacy and safety of NKTR-214 in combination with Roche's RHHBY Tecentriq (atezolizumab) and Merck's MRK Keytruda (pembrolizumab). Notably, this PROPEL study complements the company's ongoing PIVOT trial.

Additionally, in May 2017, Nektar had entered into a research collaboration with Takeda Pharmaceuticals to explore the combination of NKTR-214 with five oncology compounds from Takeda's cancer portfolio.

Nektar Therapeutics Price

Nektar Therapeutics Price | Nektar Therapeutics Quote

Nektar carries a Zacks Rank #4 (Sell).

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

Wall Street's Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

(We are reissuing this article to correct a mistake. The original article, issued Thursday, February 15, 2018, should no longer be relied upon.)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Merck & Company, Inc. (MRK): Free Stock Analysis Report

Nektar Therapeutics (NKTR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK BMY NKTR

Other Topics

Stocks

Latest Markets Videos